Pharmacokinetic of a very low molecular weight heparin in chronic renal failure.
The pharmacokinetic characteristics of a low molecular weight heparin (LMWH) (Cy 222; mean mw: 2500 daltons) are studied in 24 patients with 3 degrees of chronic renal failure (CRF) stage I (creatinine clearance between 50 and 30 ml/mn), stage 2 (creatine clearance between 30 and 10 ml/mn), stage 3 (creatinine clearance below 10 ml/mn). Patients with CRF have significantly higher values of anti Xa activity at 3 hours (p less than 0.05), 5 hours (p less than 0.05), and at 8 hours (p less than 0.03) after injection than controls, CMAX values, VDSS and AUC do not differ, whereas patients with the highest stage of CRF are characterised by the most important t1/2 a (p less than 0.001) and the smallest total body clearance (p less than 0.01). Consequences of these disturbances of pharmacokinetic characteristics have to be evaluated before adequate posology of heparin fragments could be determined in patients with CRF.
Hory
B
B
Department of Nephrology and Internal Medicine, CHU Saint-Jacques, Besançon, France.
Claudet
M H
MH
Magnette
J
J
Bechtel
P
P
Bayrou
B
B
D003404:Creatinine / Q000097:blood; D004341:Drug Evaluation; D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000145:classification / Q000150:complications / Q000378:metabolism* / Q000628:therapy; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D006435:Renal Dialysis; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control
D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight; D003404:Creatinine